{"id":"e0e9feff-36eb-59ed-88c8-3ca7d2be4583","stable_key":"33bef151-bdc7-5892-aff6-0345ab149739:nattokinase-cleaves-and-inactivates-pai-1","predicate":"proteolyzes","statement":"Subtilisin NAT cleaved active recombinant PAI-1 at its reactive-site Arg346-Met347 bond and PAI-1 lost specific activity dose-dependently over 0.02-1.0 nM, with a half-maximal effect near 0.1 nM.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"0decc2bc-639e-502c-998a-1965f044561d","mechanism_event_label":"Subtilisin NAT cleaved active recombinant PAI-1 at its reactive-site Arg346-Met347 bond and PAI-1 lost specific activity dose-dependently over 0.02-1.0 nM, with a half-maximal effect near 0.1 nM.","subject":{"id":"6b03a125-209a-5060-8b35-ec9e0e54033c","slug":"nattokinase","display_name":"Nattokinase / subtilisin NAT","entity_type_key":"peptide"},"object":{"id":"b4b08646-fd4e-5294-8fab-b29e62ff988a","slug":"human-serpine1","display_name":"Human SERPINE1 / plasminogen activator inhibitor 1","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"0decc2bc-639e-502c-998a-1965f044561d","stable_key":"33bef151-bdc7-5892-aff6-0345ab149739:nattokinase-cleaves-and-inactivates-pai-1-event","event_type":"biochemical_relationship","label":"Subtilisin NAT cleaved active recombinant PAI-1 at its reactive-site Arg346-Met347 bond and PAI-1 lost specific activity dose-dependently over 0.02-1.0 nM, with a half-maximal effect near 0.1 nM.","description":"Purified-protein proteolysis with MALDI-TOF and peptide sequencing","status":"provisional","compartment":null,"participants":[{"entity":{"id":"6b03a125-209a-5060-8b35-ec9e0e54033c","slug":"nattokinase","display_name":"Nattokinase / subtilisin NAT","entity_type_key":"peptide"},"role":"acting component","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"b4b08646-fd4e-5294-8fab-b29e62ff988a","slug":"human-serpine1","display_name":"Human SERPINE1 / plasminogen activator inhibitor 1","entity_type_key":"protein"},"role":"component the finding is about","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"duration","value_text":"Not stated here","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Recombinant human PAI-1","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Subtilisin NAT, 0.02-1.0 nM","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"The substrate was active recombinant prokaryotic PAI-1. Whether latent or vitronectin-bound PAI-1 is cleaved was not established by this work or by anything else read here.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"organism","value_text":"Recombinant human PAI-1","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Subtilisin NAT cleaved active recombinant PAI-1 at its reactive-site Arg346-Met347 bond and PAI-1 lost specific activity dose-dependently over 0.02-1.0 nM, with a half-maximal effect near 0.1 nM.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"The profibrinolytic enzyme subtilisin NAT purified from Bacillus subtilis Cleaves and inactivates plasminogen activator inhibitor type 1. (2001) https://pubmed.ncbi.nlm.nih.gov/11325965/ DOI: 10.1074/jbc.M101751200","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"In vitro","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"Purified-protein proteolysis with MALDI-TOF and peptide sequencing","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"05ca14d5-e9a3-574e-b89f-7267a5454b56","evidence_kind":"source_excerpt","locator":"Lines 136-136","start_line":136,"end_line":136,"excerpt":"Subtilisin NAT cleaved active recombinant PAI-1 at its reactive-site Arg346-Met347 bond and PAI-1 lost specific activity dose-dependently over 0.02-1.0 nM, with a half-maximal effect near 0.1 nM.","model_system":"Recombinant human PAI-1","directness":"reported_statement","verification_status":"source_derived_draft","notes":"","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"41cb127c-1c23-53aa-b7d0-5ec7f6fa3c99","stable_key":"import-33bef151-bdc7-5892-aff6-0345ab149739","title":"Nattokinase: what the purified enzyme cleaves, what survives being eaten, and the gap between the two (2026-09-23)","document_type":"imported_text","citation_label":"Original AI-assisted curation built from a supplied entity-first document of 105 entities and 129 claims. Every reference in that document was resolved against live PubMed with its abstract read and its DOI cross-checked on 2026-09-23, and the EFSA novel-food opinion was retrieved and read in full. That check corrected two PMIDs that pointed at unrelated papers, two DOIs, and two papers recorded as carrying no erratum that do carry one; it also reversed three findings the supplied document had stated backwards. Two papers carry a published correction, recorded as such and not as a retraction. Three sources are not indexed in PubMed and are cited by what they have. Laboratory lineages are recorded, so the four papers from one group, the three from another and the two readings of a single applicant dossier cannot be counted as separate lines of support. Study-specific doses, units, populations and limitations retained; activity units are never converted between systems. Not publisher full text.","file_path":"","sha256":"34fc46e0e849d06bfa13cb099a79b50679dd6fd0de8a5a0575326afdde3259c1","revision_id":"efd063e6-e982-5f6e-a4b8-6f2ffe4185ce","review_status":"unverified_draft","notes":""}}],"relations":[{"id":"a553ddb9-4d55-58ed-aa41-f7180a2a3aa2","relation_type":"limits_translation_of","notes":"A half-maximal effect at 0.1 nM in a purified system says nothing about whether 0.1 nM is ever reached in blood.","source_claim_id":"140e1014-8105-56ca-b13a-76fe0d42e8d9","source_claim_key":"33bef151-bdc7-5892-aff6-0345ab149739:efsa-could-not-conclude-on-absorption-of-the-active-enzyme","source_statement":"EFSA concluded that the information provided on absorption, distribution, metabolism and excretion did not allow conclusions to be drawn on the absorption of active nattokinase or any functional metabolites derived from it.","target_claim_id":"e0e9feff-36eb-59ed-88c8-3ca7d2be4583","target_claim_key":"33bef151-bdc7-5892-aff6-0345ab149739:nattokinase-cleaves-and-inactivates-pai-1","target_statement":"Subtilisin NAT cleaved active recombinant PAI-1 at its reactive-site Arg346-Met347 bond and PAI-1 lost specific activity dose-dependently over 0.02-1.0 nM, with a half-maximal effect near 0.1 nM."}],"conflicts":[],"corrections":[],"research":null}